Presentations by Event

ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens, ECCMID, April 2017

Ruben Tommasi, ECCMID 2017

Program(s): durlobactam (etx2514)

ETX2514 restoration of sulbactam activity against multidrug resistant Acinetobacter baumannii correlates with β-lactamase inhibition in vitro and in vivo,

Alita Miller, ECCMID 2017

Program(s): durlobactam (etx2514)

Discovery of ETX2514, a novel, rationally designed inhibitor of Class A, C and D β–lactamases, for the treatment of Gram-negative infections

Thomas Durand-Reville, ACS 2017

Program(s): durlobactam (etx2514)

Pathogen-directed strategies at Entasis Therapeutics

Alita Miller, SDRI 2017

Program(s): durlobactam (etx2514)